Sonoma Pharmaceuticals Inc (NASDAQ:SNOA)

CAPS Rating: 1 out of 5

The Company has developed and it manufactures and markets, a family of products intended to prevent and treat infections in chronic and acute wounds.

SNOA News and Commentary

Caps

This ticker is not currently Ratable.

Add Stock to CAPS Watchlist

All Players

53 Outperform
14 Underperform
 

All-Star Players

5 Outperform
7 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top SNOA Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Casew (< 20)
Submitted February 25, 2012

When this company went public back in 2007, it's share price peaked at around $11. It has steadily gone down since then and now typically trades at a little over $1. What's interesting about this is that it's revenue has actually grown from $94,000… More

chris293 (64.23)
Submitted November 11, 2013

OCLS seems to have a funny problem, when they have increases in revenue, they company seems to have bigger losses in earning per share. Can anyone explain this?

SNOA VS S&P 500 (SPY)

Recent Community Commentary

Read the most recent pitches from players about SNOA.

Recs

0
Member Avatar Tiffany10 (< 20) Submitted: 9/25/2015 6:44:51 PM : Outperform Start Price: $6.80 SNOA Score: -70.33

Animals that suffer from any skin disorder will greatly benefit from using this product. owners will feel relieved by using a product that comforts and heals their pets...which there are a lot of.

Recs

0
Member Avatar NHWeston102 (59.86) Submitted: 7/8/2015 12:59:56 PM : Outperform Start Price: $8.25 SNOA Score: -73.18

Hydrogel gives OCLS a real product and, thereby, a chance to recover its titanic losses and perhaps a partnership with one of the Pharma Whales.

Recs

0
Member Avatar s2dbaker (81.64) Submitted: 7/22/2014 9:42:39 PM : Outperform Start Price: $14.50 SNOA Score: -102.03

This stock will never go down again.

Leaderboard

Find the members with the highest scoring picks in SNOA.

Score Leader

zzlangerhans

zzlangerhans (99.85) Score: +245.53

I know shareholders were disappointed that Facebook's acquisition turned out to be the wrong Oculus, but don't give up hope. Maybe Zuckerberg will buy this Oculus to bleach his face the next time his zits break out.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
IndexTrojan 67.14 1/26/2007 Underperform 5Y $277.20 -98.32% +99.17% +197.49 1 Comment
joezhou < 20 2/9/2011 Underperform 5Y $77.35 -93.98% +101.43% +195.40 0 Comment
mainakn 73.65 2/9/2011 Underperform 3W $77.35 -93.98% +101.43% +195.40 0 Comment
acecannon < 20 7/31/2007 Underperform 5Y $287.00 -98.38% +89.54% +187.92 0 Comment
michaelamanuel 72.73 7/27/2007 Underperform 1Y $352.10 -98.68% +89.15% +187.82 0 Comment
bpork100 82.81 1/10/2014 Underperform 5Y $18.50 -74.81% +44.77% +119.58 0 Comment
chris293 64.23 11/14/2013 7/16/2015 Underperform 1Y $13.60 -65.74% +49.16% +114.90 1 Comment
LarkinSoft 99.88 1/19/2016 Underperform 5Y $4.60 +1.30% +40.19% +38.89 0 Comment
thehammer01 96.97 11/30/2016 Underperform 5Y $4.79 -2.71% +20.76% +23.48 0 Comment
anchak 99.89 9/6/2017 Underperform NS $5.40 -13.70% +7.95% +21.65 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackBWS 97.27 3/21/2014 Underperform NS $26.45 -27.98% -0.07% +27.90 4/1/2014 @ $19.05 0 Comment
TrackZacks < 20 8/21/2012 Outperform 3M $32.20 -17.39% -2.54% -14.85 11/9/2012 @ $26.60 1 Comment
TrackRodmanRen < 20 7/18/2007 Outperform NS $378.00 -90.74% -40.11% -50.63 11/7/2008 @ $35.00 0 Comment

Featured Broker Partners